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Introduction
In healthcare and, specifically
anesthesia, there are many conditions
that require various considerations by
the prudent provider. An example of a
condition requiring special attention is
myasthenia gravis. Myasthenia gravis is
an autoimmune disease in which
skeletal muscle weakness and rapid
fatigue result from destruction of
nicotinic acetylcholine receptors [7].
Although the prevalence is not
overwhelmingly high with most recent
estimates of prevalence around 14 to 20
per 100,000 people in the United States
[5] and 20 per 100,000 worldwide [9],
inappropriate perioperative
management of those with this ailment
can result in serious consequences.
Understanding the pathophysiology,
various treatments (both surgical and
medical), and anesthetic implications
can result in better outcomes for
individuals with myasthenia gravis that
require surgery.

Case Study
Mr. Smith, a 52-year-old male, presents
to his primary care physician whom he
hasn’t seem in nearly ten years because
not only does he need a physical before
his carpal tunnel surgery planned for
next month, but also because he has not
been feeling well. Mr. Smith has been
experiencing generalized muscle
weakness that, at times, leaves him
feeling short of breath. In addition to
fatigue that does seem to resolve with
rest, Mr. Smith has also been
experiencing double vision, a
“fluttering” sensation of his heart,
difficulty swallowing, and drooping of
his eyelid. After several blood tests were
negative, including normal glucose and
thyroid panel, and a thorough
neurological examination was
performed, Mr. Smith’s physician
suspected myasthenia gravis so he
ordered a tensilon test, which confirmed
the diagnosis of myasthenia gravis.
Mr. Smith presents with classic
symptoms of myasthenia gravis and is
within the typical age range for disease
presentation in men, which is between
50 and 60 years of age [8]. Weakness
commonly affects the muscles of one or
both eyes leading to ptosis and diplopia
[4] and the age of onset in men is
typically Visual disturbances affect more
than half of patients with myasthenia
gravis. Fatigue that resolves with rest
and arrhythmias that result of
inflammation of the myocardium are
also symptoms common to the patient
with myasthenia gravis [8]. Diagnosis of
myasthenia gravis is not always
straightforward and can be difficult at
times. Various blood tests exist which
include measurement of serum
antibodies against acetylcholine
receptors and muscle-specific receptor
tyrosine kinase (MuSK) with the latter
being present in nearly 40% of
individuals with myasthenia gravis.
Perhaps the most well known diagnostic
for myasthenia gravis is the tensilon test
in which tensilon, also known as
edrophonium, is administered which
inhibits the breakdown of acetylcholine.
The increased amount of acetylcholine
in an individual with myasthenia gravis
will cause a momentary improvement of
weakness. Other tests that can assist in
the diagnosis of myasthenia gravis
include electromyography, radiologic
imaging of the chest and neck to assess
for thymus alterations, and pulmonary
function tests [10].

Significance of
Pathophysiology

Pathophysiology
To understand the pathophysiology of myasthenia gravis, one
must first have an understanding of skeletal muscle
depolarization and the receptors involved. When an electrical
impulse reaches the presynaptic nerve terminal, an influx of
calcium triggers the release of presynaptic acetylcholine.
Approximately 150 to 200 vesicles that contain nearly 10,000
molecules of acetylcholine each are released into the synaptic cleft
and bind to nicotinic acetylcholine receptors. Nicotinic
acetylcholine receptors are located on postsynaptic folds on motor
end plates, which are located in close proximity to skeletal muscle.
The binding of acetylcholine to the alpha sub-unit of the nicotinic
acetylcholine receptor causes a conformational change in the
receptor, opening a channel that allows for a rapid influx of
sodium ions. The rapid influx of sodium ions depolarizes the
motor end plate and skeletal muscle, which allows for muscular
contraction [8]. The following picture depicts the neuromuscular
junction and acetylcholine’s role in action potential propagation.

-

Most frequent symptom is
muscle weakness.
Weakness occurs when 70%90% of nicotinic acetylcholine
receptors are lost [6].
Myasthenia gravis can classified,
or staged, according to severity
and muscles affected by the
Osserman Staging system seen
below.

[3]
Of significant importance is respiratory
muscle weakness in patients with
myasthenia gravis. Ineffective
respiratory muscle function can cause a
multitude of problems both
perioperatively and in day-to-day life.
The following schematic is a great
representation of the pathologic effects
that can result from respiratory muscle
weakness.
[1]
As mentioned earlier, myasthenia gravis is an autoimmune
disorder in which antibodies target the nicotinic acetylcholine
receptors and other proteins resulting in their destruction.
Specifically, nearly 85% of people with myasthenia gravis have
antibodies that target nicotinic acetylcholine receptors. Of the
15% that do not have anti-acetylcholine antibodies, 70% have
antibodies targeting other proteins involved in neuromuscular
transmission that includes muscle specific tyrosine kinase.
Regardless of the type of autoantibody muscle membrane
destruction is caused by antibody activation of complement,
disintegration of the postsynaptic membrane, and elimination
of the postsynaptic folds (the primary location of nicotinic
acetylcholine receptors). Investigation of thymus abnormalities
(thymomas, atrophy, or hyperplasia) is warranted in patients
with myasthenia gravis because the thymus major site for
antibody production [2].

[3]

Nursing Implications
Decreased numbers of nicotinic acetylcholine
receptors and the associated skeletal muscular
weakness have important implications for the nurse
anesthetist caring for the patient with myasthenia
gravis perioperatively. A medication type frequently
utilized by the nurse anesthetist to facilitate tracheal
intubation and provide a motionless surgical field for
the surgeon is neuromuscular blockers (NMBs). The
two types of paralytics utilized today are depolarizing
NMBs and non-depolarizing NMBs [11]. The only
depolarizing NMB in use today is succinylcholine.
Chemically, succinylcholine is composed of two
molecules of acetylcholine (known as diacetylcholine)
and causes muscular paralysis by joining to a nicotinic
acetylcholine receptor causing a sustained muscular
depolarization, preventing further action potentials
from propagating. It differs from acetylcholine in that
it is metabolized by pseudocholinesterase rather than
acetylcholinesterase [8]. Due to the similarities
between succinylcholine and acetylcholine, it is not
surprising that patients with myasthenia gravis are
often resistant to this medication, necessitating
increased dosages to achieve acceptable paralysis
(usually 2.5 times more).
Patients with myasthenia gravis, however, are
considerably more sensitive to non-depolarizing
NMBs, which achieve paralysis by binding to nicotinic
acetylcholine receptors and preventing depolarization
[8]. For example, in patients with myasthenia gravis,
the potency of atracurium and vecuronium, two nondepolarizing NMBs, potency is increased two times.
Because of the increased potency, caution must be
used with non-depolarizers. If a non-depolarizing
agent is needed, the initial dose should be reduced by
50-67% and closely monitored with a peripheral
nerve stimulator. Intravenous induction agents like
propofol or etomidate and/or volatile anesthetics like
desflurane can be used to facilitate endotracheal
intubation, however, the degree of respiratory
depression can be magnified so caution needs to be
exercised with these agents as well. Similar to
induction agents, opioids can cause exacerbate
respiratory muscle weakness and too need to be used
with caution. Because of the profound respiratory
weakness than can result postoperatively, ventilator
support is frequently needed in patients with
myasthenia gravis [11]. Some experts recommend
discontinuation of cholinesterase inhibitors,
medications used to treat myasthenia gravis,
preoperatively in those with mild disease as these
agents can complicate anesthetic management.
Reversal of non-depolarizing neuromuscular blockers
in these patients can result in a cholinergic crisis. It
should be noted that discontinuation of cholinesterase
inhibitors remains controversial. Finally, adequate
return of muscular strength must be ensured prior to
extubation so respiratory distress/ failure dose not
occur [8].

Conclusion
Myasthenia gravis is a disease
process that can cause profound
weakness both perioperatively
and in every day life.
Understanding the
pathophysiology of the disease,
as is seen in the case of Mr.
Smith, can provide the nurse
anesthetist with a sound basis
so as to optimally manage the
anesthetic.
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